COVID-19’s impact on bioanalytical labs-Reference-Cited by-同舟云学术

COVID-19’s impact on bioanalytical labs

Published:2021-08 Issue:15 Volume:13 Page:1169-1171
ISSN:1757-6180
Container-title:Bioanalysis
language:en
Short-container-title:Bioanalysis

Author:

Lavelle Amy¹,Micheli Janine¹

Affiliation:

1. Immunochemistry R&D, PPD, 2244 Dabney Road, Richmond, VA 23230, USA

Abstract

Tweetable abstract One year later, the impact of the COVID-19 pandemic on business practices, supply chains, timelines and analytical needs for COVID-19 clinical trials have been felt across the bioanalytical community, as therapeutics may now require SARS-CoV-2 antigen and serological testing.

Publisher

Future Science Ltd

Subject

Medical Laboratory Technology,Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,General Medicine,Analytical Chemistry

Link

https://www.future-science.com/doi/pdf/10.4155/bio-2021-0103

Reference5 articles.

1. Globaldata PLC. Coronavirus disease 2019 pharma executive briefing. 59 (2021). https://pharma.globaldata.com/Analysis/TableOfContents/Coronavirus-Disease-COVID-19-Pharma-Executive-Briefing-May-18-2021-ReportSectorId=802954

2. Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2

3. US FDA. In Vitro Diagnostics EUAs – molecular diagnostic tests for SARS-CoV-2. http://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-molecular-diagnostic-tests-sars-cov-2

4. US FDA. In Vitro Diagnostics EUAs – serology and other adaptive immune response tests for SARS-CoV-2. http://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-serology-and-other-adaptive-immune-response-tests-sars-cov-2

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 2023 White Paper on Recent Issues in Bioanalysis: Deuterated Drugs; LNP; Tumor/FFPE Biopsy; Targeted Proteomics; Small Molecule Covalent Inhibitors; Chiral Bioanalysis; Remote Regulatory Assessments; Sample Reconciliation/Chain of Custody (PART 1A – Recommendations on Mass Spectrometry, Chromatography, Sample Preparation Latest Developments, Challenges, and Solutions and BMV/Regulated Bioanalysis PART 1B - Regulatory Agencies' Inputs on Regulated Bioanalysis/BMV, Biomarkers/IVD/CDx/BAV, Immunogenicity, Gene & Cell Therapy and Vaccine);Bioanalysis;2024-05-02

2. Perspectives on a flexible strategy for the management of nonregulated bioanalysis;Bioanalysis;2023-02

3. Biological Matrix Supply Chain Shortages: More Matrices Are Now Rare—the Case for Surrogate Matrices;The AAPS Journal;2022-03

4. Special Focus Issue - COVID-19: bioanalytical considerations, contributions and lessons – part 1;Bioanalysis;2021-08